Catenin beta-1 – Transcription factor 7-like 2 protein-protein interface (β-catenin/TCF4 interface)

The Catenin beta-1 – Transcription factor 7-like 2 (TCF4) protein-protein interface is a critical regulatory node in the canonical Wnt signaling pathway [1.1.2, 1.3.1]. Under physiological conditions, Catenin beta-1 translocates to the nucleus upon Wnt stimulation, where it binds to TCF/LEF family transcription factors, primarily TCF4, to drive the expression of genes involved in cell proliferation, differentiation, and stem cell maintenance [1.1.4, 1.4.1]. In many cancers, particularly colorectal cancer, mutations in APC or CTNNB1 lead to the constitutive stabilization and nuclear accumulation of Catenin beta-1, resulting in the uncontrolled transcription of oncogenes such as MYC and CCND1 [1.3.3, 1.4.3]. Therapeutic strategies targeting this interface aim to disrupt the physical interaction between Catenin beta-1 and TCF4 using small molecules or peptidomimetics, thereby silencing the oncogenic transcriptional program [1.2.1, 1.5.4]. However, because Wnt signaling is essential for the homeostasis of normal tissues like the intestinal epithelium and bone, achieving a therapeutic window without significant on-target toxicity remains a major challenge in drug development [1.3.1, 1.5.2].

Other names

CTNNB1/TCF4 interface [1.1.1]β-catenin/TCF7L2 complex [1.4.5]Wnt/β-catenin transcription complex [1.3.4]Catenin beta-1 – Tcf4 protein-protein interface

Inhibition of the protein-protein interaction between Catenin beta-1 and Transcription factor 7-like 2 (TCF4), preventing the formation of the active transcriptional complex and subsequent expression of Wnt target genes [1.1.4, 1.2.4].